Top 2 Cannabis Stocks to Buy for the Next Decade

While the cannabis stocks have burnt massive investor wealth, two companies may offer significant upside potential for long-term investors.

| More on:
edit Jars of marijuana

Image source: Getty Images

While the equity markets have recently entered bear markets, cannabis investors have seen a steady decline in their portfolio value for the last 12 months. Several pot stocks are down close to 80% from record highs, wiping out millions in market value.

We know that cannabis companies are grappling with lower-than-expected demand due to the slow rollout of retail stores in major Canadian provinces. As these provinces start increasing the number of licenses, inventory levels of several marijuana companies will move lower, thereby reducing the number of write-offs.

The cannabis industry is still at a nascent stage and is expected to grow at an exponential rate in the coming years. So while most pot stocks are at 52-week lows, the upside potential is massive.

Here we look at two such cannabis stocks that are solid bets for the coming decade.

MediPharm Labs is trading 79% below record highs

Shares of MediPharm Labs (TSX:LABS) are trading at $1.59, which is 79% below record highs. This Canada-based company specializes in pharmaceutical-grade production of cannabis. It focuses on distillation and cannabinoid isolation and purification.

It has a 70,000 square foot facility with a production capacity of 30,000 kilograms. The company has spent significant resources to develop advanced extraction technology and provide safe and accurately measured cannabis products to customers.

Last May, MediPharm announced a supply agreement with Cronos Group. According to this contract, MediPharm will supply Cronos with $30 million of cannabis concentrate over the next 18 months — a figure that’s expected to rise to $60 million in two years.

In September 2019, MediPharm entered into a two-year manufacturing agreement with Cronos for filling and packaging of vaping devices.

These agreements will result in a steady stream of income for MediPharm. Unlike most cannabis stocks, however, MediPharm is posting an adjusted net profit. According to consensus estimates, the company’s revenue is expected to touch $133.7 million in 2019 and $187 million in 2020, up from $7.67 million in 2018.

A price-to-earnings multiple of 11.4 and a price to 2020 sales ratio of 1.11 makes MediPharm one of the cheapest marijuana companies in Canada.

A cannabis landlord

What’s better than a profitable pot stock? One that pays a dividend. Innovative Industrial Properties (NYSE:IIPR) is a cannabis-focused real estate investment trust. The company acquires, owns and manages properties leased to licensed operators. IIPR acquires properties through sale-leaseback transactions and third-party purchases.

Cannabis is still illegal at the federal level in the United States, which makes it difficult for companies to raise debt capital. That’s where IIPR comes in, making it easier for licensed producers to focus on manufacturing on top-quality products and cut capital spending on property acquisition.

IIPR continues to grow top-line by property acquisition. It now owns 51 properties totaling 3.2 million square feet with an average lease term of 15.6 years.

IIPR stock is currently trading 63% below record highs, which has increased its dividend yield to a tasty 8.6%. This cannabis REIT is trading at an attractive forward price to earnings multiple of 14, while analysts expect earnings to grow by 81.3% in 2020 and 55.4% in 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of and recommends Innovative Industrial Properties. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »